Drug Profile
Research programme: psychiatric disorder therapeutics - Pierre Fabre
Alternative Names: 94517; F 15063; F 15441; F 16615; F 94517Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in France (PO)
- 19 Nov 2008 Preclinical pharmacodynamics data on F 16615 and F 15063 presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,